Abstract
We investigated the efficacy of lamivudine treatment in inducing a primary and sustained response in naïve pediatric patients with immune-tolerant chronic hepatitis B viral (HBV) infection. Lamivudine was used (maximum 100 mg/day) for an average of 35 months (16-60 months) for 17 patients, while 6 patients were untreated. All the treated patients became HBV-DNA negative in the twelfth month of therapy with an average of 7 months, however none of them had a sustained virological response. They all became HBV-DNA positive by the twentieth month on average. One patient had significant improvement in liver histology. No side effects were observed. Spontaneous HBV-DNA clearance or HBe seroconversion was obtained in none of the untreated cases. This study suggests that lamivudine cannot induce complete viral control in HBV pediatric immune-tolerant patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
